Version history

{
  "session_id": "sess_SDA-BIOMNI-BINDER_D-0657a9ed",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "mini-max",
  "action": "synthesize",
  "content": "\n\n{\n  \"ranked_hypotheses\": [\n    {\n      \"title\": \"Structure-Based Targeting of the NACore β-Sheet Interface (Reframed as Fibril Elongation Inhibitor)\",\n      \"description\": \"Computational design targeting the NACore (residues 68–78) steric zipper interface critical for β-strand stacking and fibril elongation. Reframed from nucleation targeting to fibril end-capping based on Skeptic critique demonstrating that cryo-EM structures (6H6B) represent mature fibril end-states, not nucleation intermediates. Designed binders would occupy the self-complementary interface driving elongation, functioning as dominant-negative caps on growing fibril ends rather than blocking primary nucleation. Incorporates polymorphic fibril structures to account for strain diversity.\",\n      \"target_gene\": \"SNCA\",\n      \"composite_score\": 0.65,\n      \"evidence_for\": [\n        {\"claim\": \"NACore is minimal aggregation-prone segment; G73A mutation reduces aggregation kinetics\", \"pmid\": \"15475202\"},\n        {\"claim\": \"Peptide inhibitors derived from NACore block fibril formation in cellular models\", \"pmid\": \"19815675\"},\n        {\"claim\": \"Cryo-EM structures provide high-resolution template for binder docking\", \"pmid\": \"31036965\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Cryo-EM structures represent end-states not nucleation intermediates; structural continuity not demonstrated\", \"pmid\": \"31036965\"},\n        {\"claim\": \"Familial PD mutations distributed throughout protein, suggesting multiple nucleation surfaces\", \"pmid\": \"12595690\"},\n        {\"claim\": \"C-terminal truncations accelerate aggregation, indicating region outside NACore contributes to nucleation\", \"pmid\": \"11592929\"}\n      ]\n    },\n    {\n      \"title\": \"Rational Design of Aggregation Competing Sequences as Dominant-Negative Competitors\",\n      \"description\": \"Incorporation of computed aggregation-blocking sequences into designed scaffolds (40–80 residue minibinders) that function as dominant-negative competitors. These sequences mimic the C-terminal aggregation interface (residues 100–140) but integrate into designed binder scaffolds rather than fibrils, acting as molecular sponges that cap growing fibril ends or sequester wild-type αS. Peptide-based inhibitors derived from this region demonstrate efficacy in cellular models; designed scaffolds improve stability and cellular delivery.\",\n      \"target_gene\": \"SNCA\",\n      \"composite_score\": 0.62,\n      \"evidence_for\": [\n        {\"claim\": \"C-terminal fragments accelerate aggregation; peptide inhibitors from this region show efficacy\", \"pmid\": \"11737276\"},\n        {\"claim\": \"C-terminal region facilitates cross-β interactions in fibril formation\", \"pmid\": \"23831613\"},\n        {\"claim\": \"Designed scaffolds can improve stability and cellular delivery over free peptides\", \"pmid\": \"30626073\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"C-terminal truncations accelerate aggregation, suggesting this region may promote nucleation kinetics\", \"pmid\": \"11592929\"},\n        {\"claim\": \"Aggregation-blocking sequences may themselves aggregate if not properly scaffolded\", \"pmid\": \"22101819\"}\n      ]\n    },\n    {\n      \"title\": \"Oligomer-Specific Surface Epitope Blockade\",\n      \"description\": \"Computational design of binders recognizing transient quaternary surfaces unique to spherical αS oligomers—distinct from monomeric αS or mature fibrils—exploiting the toxic oligomer hypothesis. These binders sterically occlude membrane-permeabilizing interfaces or block templated seeding surfaces. Limited by the transient nature of oligomers making structural characterization difficult and accurate computational targeting challenging.\",\n      \"target_gene\": \"SNCA\",\n      \"composite_score\": 0.55,\n      \"evidence_for\": [\n        {\"claim\": \"Conformation-specific antibodies (ASyn295, NJ001) validate oligomers display unique surfaces\", \"pmid\": \"23643722\"},\n        {\"claim\": \"Oligomers exhibit distinct biological activities from monomers and fibrils\", \"pmid\": \"20167329\"},\n        {\"claim\": \"Toxic oligomer hypothesis supported by multiple cellular and animal models\", \"pmid\": \"21254973\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Transient oligomer nature makes structural characterization difficult for accurate computational targeting\", \"pmid\": \"25636995\"},\n        {\"claim\": \"Oligomer population heterogeneity complicates identification of druggable surfaces\", \"pmid\": \"28720782\"}\n      ]\n    },\n    {\n      \"title\": \"Cryptic Pocket Stabilization to Prevent Conformational Conversion\",\n      \"description\": \"De novo design of minibinders (40–80 residue scaffolds) targeting cryptic allosteric pockets on monomeric αS that, when stabilized, trap the protein in a non-aggregation-competent conformation. Uses ensemble-based modeling or AlphaFold2-generated conformational states to identify pockets that shift the monomer ensemble away from β-sheet-prone states. Limited by computational challenges in designing for intrinsically disordered targets where pocket identification depends on sampled conformational states.\",\n      \"target_gene\": \"SNCA\",\n      \"composite_score\": 0.45,\n      \"evidence_for\": [\n        {\"claim\": \"EGCG remodels aggregates demonstrating ligand-induced conformational changes are possible\", \"pmid\": \"22365486\"},\n        {\"claim\": \"AlphaFold2 can generate conformational states for IDP pocket identification\", \"pmid\": \"34758328\"},\n        {\"claim\": \"Ensemble-based modeling approaches show promise for IDP targets\", \"pmid\": \"33424157\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"αS monomers adopt heterogeneous conformations; pocket identification depends on sampled states\", \"pmid\": \"33424157\"},\n        {\"claim\": \"Designing for intrinsically disordered targets remains computationally challenging\", \"pmid\": \"34758328\"},\n        {\"claim\": \"Binding-induced conformational selection may not prevent aggregation if kinetics favor β-sheet formation\", \"pmid\": \"22365486\"}\n      ]\n    }\n  ],\n  \"synthesis_summary\": \"TheSynthesized ranking prioritizes H1 (NACore β-sheet interface targeting, score 0.65) as the most evidence-supported approach, reframed as a fibril elongation inhibitor rather than nucleation blocker based on Skeptic analysis demonstrating that cryo-EM structures represent end-states. H4 (aggregation competing sequences, score 0.62) ranks second with strong peptide-inhibitor precedent and improved scaffold design potential. H2 (oligomer-specific targeting, score 0.55) benefits from conformation-specific antibody validation but faces transient oligomer characterization challenges. H3 (cryptic pocket stabilization, score 0.45) remains most speculative due to computational IDP challenges. Key knowledge gaps include: primary vs. secondary nucleation distinction affecting all hypotheses, polymorphic fibril strain diversity requiring multi-target strategies, and validation pathway for BBB penetration in therapeutic development. Falsification experiments using seeded growth kinetics with substoichiometric seed ratios will differentiate fibril-end capping (H1, H4) from nucleation blocking mechanisms.\",\n  \"knowledge_edges\": [\n    {\"source_id\": \"H1\", \"source_type\": \"hypothesis\", \"target_id\": \"H4\", \"target_type\": \"hypothesis\", \"relation\": \"shares_fibril_end_targeting_strategy\"},\n    {\"source_id\": \"H2\", \"source_type\": \"hypothesis\", \"target_id\": \"H1\", \"target_type\": \"hypothesis\", \"relation\": \"oligomer_targeting_supplements_fibril_elongation_inhibition\"},\n    {\"source_id\": \"H3\", \"",
  "tokens_used": "1874"
}